CHIMERIC VSV-G PROTEINS AS NUCLEIC ACID TRANSFER VEHICLES
    5.
    发明申请
    CHIMERIC VSV-G PROTEINS AS NUCLEIC ACID TRANSFER VEHICLES 有权
    CHEMERIC VSV-G蛋白作为核酸转运车

    公开(公告)号:US20150306248A1

    公开(公告)日:2015-10-29

    申请号:US14695265

    申请日:2015-04-24

    申请人: Sujata Acharjee

    发明人: Sujata Acharjee

    摘要: The design and generation of a number of chimeric VSV-G (or VSV-G variants) proteins are used as transfer vehicles to enhance delivery of nucleic acids like plasmid DNA, single and double stranded DNA and RNA, and antisense oligonucleotides into human and animal cells. These chimeric VSV-G protein-nucleic acid transfer vehicles have widespread applications to deliver nucleic acids for exon skipping and gene delivery for gene replacement in human and animals.

    摘要翻译: 使用许多嵌合VSV-G(或VSV-G变体)蛋白质的设计和生成作为转运载体来增强核酸如质粒DNA,单链和双链DNA和RNA以及反义寡核苷酸向人和动物的递送 细胞。 这些嵌合VSV-G蛋白 - 核酸转运载体在人和动物中具有用于递送核酸用于外显子跳过和基因递送用于基因替换的广泛应用。

    Methods and Compositions for Assessing and Treating Cancer
    6.
    发明申请
    Methods and Compositions for Assessing and Treating Cancer 审中-公开
    评估和治疗癌症的方法和组合

    公开(公告)号:US20130315934A1

    公开(公告)日:2013-11-28

    申请号:US13881623

    申请日:2011-10-28

    IPC分类号: C12Q1/68

    摘要: The invention relates to methods and compositions for identifying mutations associated with cancer, such as melanoma. More particularly, the invention relates to methods and compositions for assessing particular mutations as markers for cancer, such as melanoma. Such methods and compositions allow medical providers to diagnose cancer, such as melanoma, based upon the presence of one or more particular mutations in a subject, as compared with an otherwise healthy control. The methods and compositions are also useful in guiding the type of therapy to be applied, and monitoring the effects of the therapy applied.

    摘要翻译: 本发明涉及用于鉴定与癌症相关的突变的方法和组合物,例如黑素瘤。 更具体地,本发明涉及用于评估特定突变作为癌症标志物的方法和组合物,例如黑素瘤。 与其他健康对照相比,这样的方法和组合物允许医疗提供者基于受试者中一种或多种特定突变的存在来诊断癌症,例如黑素瘤。 方法和组合物也可用于指导所应用的治疗类型,并监测所施用的治疗效果。

    Protein involved in G protein-coupled receptor mediated signal transduction with ability to mediate signal transduction from a dopamine D1 receptor or an adenosine A2A receptor to an adenylate cyclase and utilization thereof
    8.
    发明授权
    Protein involved in G protein-coupled receptor mediated signal transduction with ability to mediate signal transduction from a dopamine D1 receptor or an adenosine A2A receptor to an adenylate cyclase and utilization thereof 失效
    涉及G蛋白偶联受体介导的信号转导的蛋白质,其能够介导从多巴胺D1受体或腺苷A2A受体到腺苷酸环化酶的信号转导及其利用

    公开(公告)号:US07893203B2

    公开(公告)日:2011-02-22

    申请号:US12118247

    申请日:2008-05-09

    IPC分类号: C07K14/47

    CPC分类号: C07K14/4722

    摘要: A novel protein (Gm1) includes an amino acid sequence part having a high homology with a domain having a high homology with a GTP binding site and a GTPase site conserved among G protein α subunits and a trimer forming domain conserved among G protein α subunits. The Gm1 protein is involved in signal transduction via a G protein-coupled receptor (GPCR) stimulation. The Gm1 protein is expressed intensively in human brain, thymus, testes, spleen, small intestine, uterus and heart. A method for screening for a substance capable of regulating a cellular signal transduction employs a polynucleotide encoding the Gm1 protein.

    摘要翻译: 一种新型蛋白质(Gm1)包括与G蛋白α亚基保守的G蛋白α亚基和三聚体形成结构域在G蛋白α亚基中保守的与GTP结合位点和GTP酶位点高度同源的结构域具有高度同源性的氨基酸序列部分。 Gm1蛋白通过G蛋白偶联受体(GPCR)刺激参与信号转导。 Gm1蛋白在人脑,胸腺,睾丸,脾脏,小肠,子宫和心脏中都集中表达。 筛选能够调节细胞信号转导的物质的方法采用编码Gm1蛋白的多核苷酸。

    Atlastin
    9.
    发明授权
    Atlastin 有权
    阿特拉斯汀

    公开(公告)号:US07649088B2

    公开(公告)日:2010-01-19

    申请号:US11523305

    申请日:2006-09-19

    IPC分类号: C07H21/02 C07H21/04

    摘要: The present invention relates to methods and compositions of a novel gene and the peptide encoded by the gene. Mutations in the gene, named atlastin, are factors in the disease Hereditary Spastic Paraplegia and related disorders. The present invention will be used for the in the research, diagnosis and treatment of these disabling diseases.

    摘要翻译: 本发明涉及新基因的方法和组合以及由该基因编码的肽。 基因突变,命名为atlastin,是疾病中的因素遗传性痉挛性截瘫及相关疾病。 本发明将用于研究,诊断和治疗这些致残性疾病。